MA
Therapeutic Areas
Tabuk Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ADI‑PEG20 (ADZODI®) | Malignant Pleural Mesothelioma and other arginine‑auxotrophic cancers | Commercial (licensed) |
| K‑CAB® (Tegoprazan) | Gastro‑esophageal reflux disease | Commercial (licensed) |
Leadership Team at Tabuk Pharmaceuticals
IS
Ismail Shehada
CEO
HR
Hatem Reda
Chief Marketing Officer
SQ
Sami Qassim
Chief Research and Development Officer
FM
Faisal Mahrous
Chief Commercial Officer
WA
Wisam AlKhatib
Chief Business Development Officer
MR
Maysara Rabah
Chief Technical Officer
GI
Georges Ibrahim
Chief Quality Officer
SS
Saad Stephan
Chief Financial Officer